GSK : to present updates on its industry-leading infectious disease portfolio at IDWeek 2022
First presentation of RSV Older Adult vaccine candidate's pivotal phase III efficacy and safety data New data showing Shingrix... | October 12, 2022
Source: marketscreener.com